Cara Therapeutics Inc to Discuss KOMFORT Phase 2 Topline Data - Conference Call Transcript - Thomson StreetEvents

Cara Therapeutics Inc to Discuss KOMFORT Phase 2 Topline Data - Conference Call Transcript

Cara Therapeutics Inc to Discuss KOMFORT Phase 2 Topline Data - Conference Call Transcript - Thomson StreetEvents
Cara Therapeutics Inc to Discuss KOMFORT Phase 2 Topline Data - Conference Call Transcript
Published Jun 30, 2022
11 pages (6887 words) — Published Jun 30, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of CARA.OQ conference call or presentation 30-Jun-22 12:30pm GMT

  
Brief Excerpt:

...Operator Good morning. My name is Liz, and I will be your conference facilitator. I'd like to welcome everyone to Cara Therapeutics call to discuss the top line results of the KOMFORT Phase II proof-of-concept study in NP. (Operator Instructions) Please be advised that this call is being recorded. I would now like to introduce Iris Francesconi, Chief Strategy Officer and Head of Investor Relations from Cara Therapeutics. Ms. Francesconi, you may begin the call. Iris Francesconi ...

  
Report Type:

Transcript

Source:
Company:
Cara Therapeutics Inc
Ticker
CARA.OQ
Time
12:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst : Congratulation on the data. A couple of questions here. One is, do you consider the duration of NP between the 2 arms as balanced, especially considering the standard deviation. And is that of a contributing factor to the outcome? Two, what explains the increased urine output and frequent urination observed in the treatment arm? Is it because of an underlying disease, I don't believe we've seen that before. Or is it because of an increased oral -- increased dose? And last, but not least, ahead, given what we know about REMITCH working in this -- in PBC with the same -- similar mechanism of action and today's positive results, what does this for mean what we should expect as a potential outcome when that data reached out in the second half?


Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : I have a few here. So how would 1 expect headache, dizziness, constipation and increased urine output to change over time with the chronic usage of Oral KORSUVA? And asked another way, I guess, is how it need be managed in potential real-world usage of this product? And how would doctors and patients think about the benefits of the product competing underlying NPH versus these risks?


Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Got it. It's still quite early, but how long do you think a Phase III trial in NP could take in? Could you potentially get those results prior to obtaining Phase III results in atopic dermatitis?


Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : And then my final question is a 2 parter. So in the event that the company decides to prioritize NP, for example, would you have enough of a safety database to file in that indication alone because you have programs running in NDD, CKD, AD and PBC as well. And the second part, specifically, what implications does the increased urine output adverse event in the KOMFORT trial mean for patients with nondialysis-dependent chronic kidney disease.

Table Of Contents

Cara Therapeutics Inc at JPMorgan Healthcare Conference Transcript – 2023-01-09 – US$ 54.00 – Edited Transcript of CARA.OQ presentation 9-Jan-23 7:15pm GMT

Cara Therapeutics Inc at Piper Sandler Healthcare Conference Transcript – 2022-12-01 – US$ 54.00 – Edited Transcript of CARA.OQ presentation 1-Dec-22 1:00pm GMT

Cara Therapeutics Inc Q3 2022 Earnings Call Transcript – 2022-11-07 – US$ 54.00 – Edited Transcript of CARA.OQ earnings conference call or presentation 7-Nov-22 9:30pm GMT

Cara Therapeutics Inc Virtual NP Day Transcript – 2022-09-20 – US$ 54.00 – Edited Transcript of CARA.OQ conference call or presentation 20-Sep-22 3:00pm GMT

Cara Therapeutics Inc Q2 2022 Earnings Call Transcript – 2022-08-08 – US$ 54.00 – Edited Transcript of CARA.OQ earnings conference call or presentation 8-Aug-22 8:30pm GMT

Cara Therapeutics Inc at Bank of America Healthcare Conference Transcript – 2022-05-10 – US$ 54.00 – Edited Transcript of CARA.OQ presentation 10-May-22 9:00pm GMT

Cara Therapeutics Inc Q1 2022 Earnings Call Transcript – 2022-05-09 – US$ 54.00 – Edited Transcript of CARA.OQ earnings conference call or presentation 9-May-22 8:30pm GMT

Cara Therapeutics Inc Research And Development Event (Virtual) Transcript – 2022-03-11 – US$ 54.00 – Edited Transcript of CARA.OQ corporate analyst meeting</ 11-Mar-22 6:00pm GMT

Cara Therapeutics Inc Q4 2021 Earnings Call Transcript – 2022-03-01 – US$ 54.00 – Edited Transcript of CARA.OQ earnings conference call or presentation 1-Mar-22 9:30pm GMT

Cara Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-10 – US$ 54.00 – Edited Transcript of CARA.OQ presentation 10-Jan-22 4:15pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Cara Therapeutics Inc to Discuss KOMFORT Phase 2 Topline Data - Conference Call Transcript" Jun 30, 2022. Alacra Store. Mar 29, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/Cara-Therapeutics-Inc-to-Discuss-KOMFORT-Phase-2-Topline-Data-Conference-Call-T15256363>
  
APA:
Thomson StreetEvents. (2022). Cara Therapeutics Inc to Discuss KOMFORT Phase 2 Topline Data - Conference Call Transcript Jun 30, 2022. New York, NY: Alacra Store. Retrieved Mar 29, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Cara-Therapeutics-Inc-to-Discuss-KOMFORT-Phase-2-Topline-Data-Conference-Call-T15256363>
  
US$ 54.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.